Skip to main content
SpringerLink
Log in

Intravesical BCG is an effective treatment for superficial bladder cancer

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lamm DL, Riggs DR. Immunotherapy of superficial bladder cancer. Clin Immunother 1994; 2: 331–41

    Article  Google Scholar 

  2. Raghavan D. Chemotherapy for bladder cancer in the elderly. Drugs Aging 1993; 3: 1–8

    Article  PubMed  CAS  Google Scholar 

  3. American Hospital Formulary Service Drug Information. Bethesda: American Society of Hospital Pharmacists, 1994: 698–9

  4. 1995 Physicians GenRx. St. Louis: Mosby-Year Book, Inc., 1995; II 187–91

  5. Sosnowski JT, Lamm DL. Immunotherapy for bladder cancer. Urol Annu 1990; 4: 123–56

    Google Scholar 

  6. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205

    Article  PubMed  CAS  Google Scholar 

  7. Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro Jr. L, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990 Mar; 143: 502–6

    PubMed  Google Scholar 

  8. Rintala E, Jauhiainen K, Alfthan O, et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette Guerin) in superficial bladder cancer. Eur Urol 1991; 20: 19–25

    PubMed  CAS  Google Scholar 

  9. Witjes JA, van der Meijden APM, Witjes WPJ, et al. A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, BCG-RIVM in pTa-pTl tumours and primary carcinoma in situ of the urinary bladder. Eur J Can 1993; 29A Part A: 1672–6

    Article  CAS  Google Scholar 

  10. Melekos MD, Chionis HS, Paranychianakis GS, et al. Intravesical 4′-epi-doxorubicin (epirubicin) versus Bacillus Calmette-Guérin. Cancer 1993 Sep 1; 72: 1749–55

    Article  PubMed  CAS  Google Scholar 

  11. Kälble T, Beer M, Staehler G. Intravesical prophylaxis with BCG versus interferon A for superficial bladder cancer [abstract]. J Urol 1994; 151(22): 233a

    Google Scholar 

  12. Herr HW. Transurethral resection and intravesical therapy of superficial bladder cancer. Urol Clin North Am 1991; 18: 525–8

    PubMed  CAS  Google Scholar 

  13. Pagano F, Bassi P, Milani C, et al. A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective? J Urol 1991; 146: 32

    PubMed  CAS  Google Scholar 

  14. Lamm DL, Crawford ED, Blumenstein BA, et al. Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study [abstract]. J Urol 1992; 147(4): 274A

    Google Scholar 

  15. Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992; 19: 565–72

    PubMed  CAS  Google Scholar 

  16. Martindale. The Extra Pharmacopoeia, 30th ed. London: Pharmaceutical Press, 1993

    Google Scholar 

  17. Rogerson JW. Intravesical bacille Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder. Br J Urol 1994; 73: 655–8

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Intravesical BCG is an effective treatment for superficial bladder cancer. Drugs Ther. Perspect 5, 1–4 (1995). https://doi.org/10.2165/00042310-199505080-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505080-00001

Keywords

Search

Navigation